Growing community of inventors

Houston, TX, United States of America

Marina Konopleva

Average Co-Inventor Count = 3.27

ph-index = 2

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 147

Marina KonoplevaMichael B Sporn (2 patents)Marina KonoplevaMichael Andreeff (2 patents)Marina KonoplevaDeepak Sampath (1 patent)Marina KonoplevaMark Merchant (1 patent)Marina KonoplevaRaymond Gilmour (5 patents)Marina KonoplevaEnsar Halilovic (3 patents)Marina KonoplevaYouzhen Wang (3 patents)Marina KonoplevaLina Han (1 patent)Marina KonoplevaNathan Arthur Brooks (1 patent)Marina KonoplevaAnna Skwarska (0 patent)Marina KonoplevaErick Morris (0 patent)Marina KonoplevaCourtney Dinardo (0 patent)Marina KonoplevaVivian Salama (0 patent)Marina KonoplevaMarina Konopleva (3 patents)Michael B SpornMichael B Sporn (29 patents)Michael AndreeffMichael Andreeff (5 patents)Deepak SampathDeepak Sampath (17 patents)Mark MerchantMark Merchant (7 patents)Raymond GilmourRaymond Gilmour (5 patents)Ensar HalilovicEnsar Halilovic (3 patents)Youzhen WangYouzhen Wang (3 patents)Lina HanLina Han (1 patent)Nathan Arthur BrooksNathan Arthur Brooks (1 patent)Anna SkwarskaAnna Skwarska (0 patent)Erick MorrisErick Morris (0 patent)Courtney DinardoCourtney Dinardo (0 patent)Vivian SalamaVivian Salama (0 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. University of Texas System (2 from 5,445 patents)

2. Dartmouth College (2 from 663 patents)

3. Genentech, Inc. (1 from 3,221 patents)

4. Eli Lilly and Company (4,443 patents)

5. Novartis Ag (3,923 patents)

6. Les Laboratoires Servier (290 patents)


3 patents:

1. 10959993 - Combination of Bcl-2 inhibitor and MEK inhibitor for the treatment of cancer

2. 7795305 - CDDO-compounds and combination therapies thereof

3. 7435755 - CDDO-compounds and combination therapies thereof

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/9/2025
Loading…